Comparative Pharmacology
Head-to-head clinical analysis: SIGNIFOR versus SOMATULINE DEPOT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SIGNIFOR versus SOMATULINE DEPOT.
SIGNIFOR vs SOMATULINE DEPOT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Somatostatin analog; inhibits growth hormone (GH), insulin-like growth factor 1 (IGF-1), and other hormones.
Somatostatin analog; binds to somatostatin receptors (mainly SSTR2 and SSTR5) with high affinity, inhibiting the secretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), and various gastrointestinal hormones.
Subcutaneous injection: 0.3 mg twice daily; Intravenous bolus: 0.9 mg (for Cushing's disease perioperatively).
90 mg subcutaneously every 4 weeks for acromegaly; 120 mg subcutaneously every 4 weeks for neuroendocrine tumors (administered every 2 weeks if progression occurs). Adjust dose based on clinical response and growth hormone/IGF-1 levels.
None Documented
None Documented
Terminal elimination half-life is approximately 5-6 hours in healthy subjects. In patients with renal impairment, half-life may be prolonged (up to 10 hours in severe impairment).
The terminal elimination half-life is approximately 23-29 days after subcutaneous injection of the depot formulation, supporting a monthly dosing interval.
Primarily renal (approximately 80% of the dose excreted unchanged in urine), with about 20% eliminated via biliary/fecal routes. Renal clearance accounts for ~70% of total clearance.
Lanreotide is primarily excreted via the biliary-fecal route. After administration, approximately 78% of a radiolabeled dose is recovered in feces, with less than 5% excreted unchanged in urine. The remainder is metabolized and eliminated via bile.
Category C
Category C
Somatostatin Analog
Somatostatin Analog